Crystal Brimer
Optometrist · Wilmington, NCNPI 1922189844
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (42.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Oculus, Inc. accounts for 66.5% of it on its own, with 24 other manufacturers making up the rest. Among optometrist clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 488 payments — averaging $1884.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oculus, Inc.$612K
- Biotissue Holdings Inc.$104K
- Sun Pharmaceutical Industries Inc.$88K
- Bausch & Lomb Americas Inc.$53K
- Lumenis BE Inc$18K
- Shire North American Group Inc$13K
- plus $33K from 19 others
What the payments were for
- Royalty or licence$388,60042%
- Consulting fees$127,10414%
- Speaking & faculty fees$366,30640%
- Travel & lodging$20,7152%
- Food & beverage$16,3182%
- Education$930%
- Entertainment$4270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oculus, Inc. | 68 | $611,601 |
| Biotissue Holdings Inc. | 40 | $103,803 |
| Sun Pharmaceutical Industries Inc. | 135 | $87,995 |
| Bausch & Lomb Americas Inc. | 106 | $52,655 |
| Lumenis BE Inc | 1 | $18,000 |
| Shire North American Group Inc | 23 | $12,606 |
| Kala Pharmaceuticals, Inc. | 12 | $9,548 |
| AbbVie(2 entities) | 28 | $7,958 |
| Lumenis, Inc | 2 | $6,120 |
| Novartis | 6 | $4,710 |
| Alcon | 14 | $1,314 |
| Optos, Inc. | 6 | $665 |
| Coopervision Inc. | 6 | $469 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $442 |
| Sight Sciences, Inc. | 6 | $338 |
| Eyevance Pharmaceuticals LLC | 7 | $221 |
| Dompe US, Inc. | 3 | $200 |
| Mallinckrodt Hospital Products Inc. | 2 | $192 |
| Oyster Point Pharma, Inc. | 5 | $175 |
| Harrow Eye, LLC | 6 | $166 |
| Tarsus Pharmaceuticals, Inc. | 4 | $129 |
| NEW World Medical,inc. | 1 | $124 |
| Quidel Corporation | 1 | $60 |
| Rxsight Inc | 1 | $45 |
| Heidelberg Engineering, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCULUS Keratograph 5M$253,920
- Keratograph$192,051
- CTR/Jenvis$123,550
- CEQUA$85,825
- XIIDRA$58,753
- MIEBO$42,442
- Keratograph 5M$22,250
- NA$19,750
- optilight$18,000
- EYSUVIS$9,461
- VUITY$3,158
- RESTASIS MULTIDOSE$2,478
- Prokera$1,861
- AmnioGraft$1,390
- PANORAMIC OPHTHALMOSCOPE$939
- OCT OPHTHALMOSCOPE$718
- BLINK NUTRITEARS$600
- LUMIGAN$544
- LOTEMAX SM$492
- NFC-700$469
How this compares
$919,563 in reported general payments places this provider in the 95th percentile of 1,326 optometrist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 35 | $1,872,885 |
| CequaCyclosporine | 75 | $79,693 |
| MieboPerfluorohexyloctane/Pf | 86 | $69,060 |
| XiidraLifitegrast | 23 | $36,105 |
| RestasisCyclosporine | 26 | $22,703 |
| TyrvayaVarenicline Tartrate | 21 | $18,020 |
| VevyeCyclosporine | 19 | $15,050 |
| EysuvisLoteprednol Etabonate | 16 | $7,858 |
| ZerviateCetirizine Hcl | 15 | $7,515 |
| Doxycycline Hyclate | 41 | $2,159 |
| Omega-3 Acid Ethyl Esters | 37 | $1,851 |
| Doxycycline Monohydrate | 14 | $707 |
| Azithromycin | 24 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $200 | $1,872,88535 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $52,655 | $105,165109 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $87,995 | $79,69375 claims |
| AbbVieRestasis | $7,958 | $22,70326 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $175 | $18,02021 claims |
| Harrow Eye, LLCVevye | $166 | $15,05019 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $9,548 | $7,85816 claims |
| Eyevance Pharmaceuticals LLCZerviate | $221 | $7,51515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 optometrist providers in North Carolina.
Other optometrist in Wilmington
- Rasika WhitesellWilmington$40K
- James FanelliWilmington$39K
- Tracey GlendenningWilmington$13K
- Chris GlendenningWilmington$11K
- Michael SchilawskiWilmington$11K
- Hilary CoxWilmington$9K
- Chad TisdaleWilmington$9K
- Osama SaidRaleigh$597K
- Ryan CorteAsheville$569K
- Sanjay PatelApex$518K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.